Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Isopropamide→

Isopropamide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
7492-32-2
Molecular formula
C23H33N2O+
Molecular weight
353.5 g/mol
Drug class
Quaternary ammonium antimuscarinicgastrointestinal antispasmodic (historical)
Mechanism of action
Competitively antagonises muscarinic acetylcholine receptors in gastrointestinal smooth muscle, reducing cholinergic tone, motility and spasm. Its quaternary ammonium structure limits central nervous system penetration.
Indications / reported uses
  • Historically used for symptomatic relief of gastrointestinal hypermotility and spasm in countries where isopropamide products were authorised; availability and current indications are jurisdiction-specific

Sources: NLM MeSH — Isopropamide · PubMed — Isopropamide anticholinergic pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Isopropamide Environmental Risk Assessment (ERA) (the Isopropamide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.